The pharma group’s third CEO of 2018 is a former tobacco-industry executive – a sector usually shunned by drugmakers. That suggests a decisive turn toward consumer goods. It’s a sensible enough idea, but the company’s timing might be off, Robert Cyran suggests.
from Reuters Video: Breakingviews https://ift.tt/2A1900V
No comments:
Post a Comment